Global mRNA and Gene Therapy Markets Project Strong Growth to 2030

Market research forecasts indicate that the global messenger RNA (mRNA) therapeutics market will reach roughly $371.8 billion by 2026 and $423.2 billion by 2030, growing at an average annual rate of about 3.3% from 2026‑2030. Expansion is driven by rising demand for personalized treatments and the application of mRNA technology beyond vaccines into oncology, rare genetic disorders, respiratory diseases and protein‑replacement therapies. Leading firms such as Pfizer, Moderna, BioNTech, Novartis, AstraZeneca and others are expanding pipelines, investing in delivery platforms and pursuing strategic acquisitions, for example BioNTech’s purchase of CureBack in 2025.

The gene‑therapy market is also projected to expand rapidly, with an estimated compound annual growth rate of 31.2% through 2026 and 13.5% from 2025‑2030. Growth is fueled by increased medical investment, advances in viral‑vector and non‑viral delivery systems, CRISPR‑based editing and supportive regulatory frameworks. Notable developments include Pfizer’s approval of a gene‑therapy for hemophilia B and Regeneron’s acquisition of Decibel Therapeutics in 2023 to strengthen its hearing‑loss and genetic‑disease portfolio. North America holds the largest market share, while the Asia‑Pacific region is expected to record the highest growth rate during the forecast period.

Overall, heightened biotech financing, strategic partnerships and a broadening of therapeutic indications are reshaping the landscape for both mRNA‑based medicines and gene‑editing treatments worldwide.